Full Press Release Details
CASI Pharmaceuticals
Receives the Delisting Decision from the Nasdaq Hearings Panel
South San Francisco, California / February 25, 2026
/ ACCESS NEWSWIRE / -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a clinical-stage biopharmaceutical company focused on developing
CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ
transplant rejection and autoimmune diseases, today announced that it has received a determination letter from the Hearings Panel
(the "Panel") of The Nasdaq Stock Market ("Nasdaq") dated February 23, 2026, notifying the Company that the
Panel determined to delist the Company's securities from Nasdaq, due to the Company's failure to satisfy the continued listing
conditions as previously disclosed. As a result, the Company securities will be suspended from trading at the open of business on February 26,
2026 and delisted from Nasdaq after the completion of certain applicable process. The Company does not intend to request a review of such
Following the delisting, the Company expects that its ordinary shares
will be quoted on the "over the counter" market operated by OTC Markets Group Inc (the "OTC") so that a trading
market may continue to exist for its ordinary shares. There is no guarantee, however, that a broker will continue to make a market in
the ordinary shares and that trading of the ordinary shares will continue on an OTC market or otherwise.
The delisting from Nasdaq will have no significant impact on the Company's
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc.
is a public biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune
fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated
an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI
owns exclusive global rights. CASI has received regulatory approvals of a Chinese Phase 1 / 2 CTA and a U.S. Phase 1 IND in adults
with chronic active renal allograft antibody-mediated rejection (AMR). In parallel,
CASI is actively recruiting and dosing patients in an ongoing Phase 1 study in immune thrombocytopenia (ITP). In addition, CASI is assessing
multiple technologies for development of a stable, high concentration protein solution for subcutaneous injection.
on CASI is available at www.casipharmaceuticals.com.
Forward Looking Statements
contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects,"
"anticipates," "future," "intends," "plans," "believes," "estimates," "confident"
and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's
strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements
in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in
press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements
that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained
in any forward-looking statement. Further information regarding these and other risks is included in the Company's filings with the SEC.
All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking
statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained